# A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

> **NCT01160211** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 369 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase Inhibitor
- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT01160211
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-05
- **Primary completion:** 2016-03-11
- **Final completion:** 2022-06-06
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160211, "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01160211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*